Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chapter 16: Prophylactic human papillomavirus vaccines.

Douglas R Lowy1, Ian H Frazer

  • 1Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health/DHHS, Building 37, Room 4106, MSC 4263, Bethesda, MD 20892, USA. drl@helix.nih.gov

Journal of the National Cancer Institute. Monographs
|June 17, 2003
PubMed
Summary

Prophylactic vaccines using human papillomavirus (HPV) L1 virus-like particles (VLPs) show promise in preventing HPV infections and cervical cancer. Ongoing trials aim to expand vaccine efficacy and accessibility globally.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of endothelial Dlc1 in embryonic vascular development and adult bone marrow hematopoiesis.

Leukemia·2026
Same author

Exceeding expectations: factors contributing to the potency of human papillomavirus vaccines.

The Lancet. Microbe·2026
Same author

The Biomarkers Consortium: 20 years of advancing precision medicine.

Nature reviews. Drug discovery·2026
Same author

Development of HPV 35 serology assays for assessment of immune responses to HPV 35 after infection and vaccination.

Human vaccines & immunotherapeutics·2026
Same author

Redox-active nitroxides enhance cisplatin efficacy against cervical cancer.

Redox biology·2026
Same author

Spatial analysis of HPV-associated cervical intraepithelial neoplastic tissues demonstrate distinct immune signatures associated with cervical cancer progression.

The Journal of pathology·2025

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Human papillomavirus (HPV) is a major cause of cervical cancer.
  • Current research focuses on prophylactic vaccines to prevent HPV infections.

Purpose of the Study:

  • To evaluate the efficacy of L1 virus-like particle (VLP) vaccines against HPV infections and cervical cancer precursors.
  • To assess the safety and immunogenicity of HPV L1 VLP vaccines in human clinical trials.

Main Methods:

  • Systemic immunization with L1 VLPs in animal models and human trials.
  • Monitoring antibody titers and protection against HPV challenge.
  • Conducting proof-of-principle efficacy trials for HPV16 L1 VLP.

Main Results:

Related Experiment Videos

  • L1 VLP vaccination induces high titers of neutralizing antibodies.
  • Vaccines are well-tolerated in humans, with antibody levels significantly higher than natural infection.
  • Early trials show excellent protection against persistent HPV16 infection and related abnormalities.

    • Conclusions:

    • HPV L1 VLP vaccines demonstrate significant potential for preventing HPV infections and reducing cervical cancer incidence.
    • Large-scale trials are planned for HPV16 and 18, with potential inclusion of HPV6 and 11.
    • Future efforts will focus on expanding vaccine types, improving global accessibility, and developing therapeutic applications.